|
|
 |
|
Viewing report
|
|
|
|
Statin Adjunct Therapy - Zetia, Revenue Protection for Zocor?
Datamonitor, May 2003, Pages: 57
Statins are undisputedly the gold standard in the treatment of dyslipidemia and more efficacious monotherapies are unlikely to be identified and developed in the near future. However, an important unmet need lies in the effective control of patients with complicated lipid profiles. Therefore, agents that can be used as adjuncts to statin therapy are being increasingly prescribed.
Scope:
- Assess the market potential for non-statin anti-dyslipidemics offering a novel mechanism of action or additional benefits to statin monotherapy
- Examine the potential of Zetia as an adjunct to statin therapy by assessing its benefits over existing adjunctive therapies
- Understand existing constraints which may limit the uptake of Zetia and potential threats to the long-term success of the drug
Report Highlights:
With statins unable to adequately control cholesterol in all patients, there remains a strong need for novel therapies that enhance the benefits of statins. In turn, Zetia is being firmly positioned as an adjunct to statin therapy, with the ability to enhance the LDL cholesterol lowering efficacy of these agents by 25%.
The combined use of a statin and Zetia as separate pills will have a negative impact on compliance and will increase the cost of lipid lowering therapy. However, the availability of a single pill combination of Zocor and Zetia may address certain of these issues.
The future sales potential of Zetia and its single pill formulation with Zocor may be threatened by third generation statins and developmental compounds with novel mechanisms of action that offer superior potency over marketed anti-dyslipidemics or have anti-atherosclerotic and anti-inflammatory benefits.
Reasons to Purchase:
- Gain an independent view of the dynamics of the statin adjunct market and assess the future potential of these agents.
- Identify the most important unmet needs within the anti-dyslipidemic market for R&D prioritization.
- Understand the factors driving versus limiting the future of Zetia, thereby identifying the opportunities and threats within the adjunctive market.
Customers who bought this item also bought
Stakeholder Insight: Dyslipidemia - Titration versus Combination Therapy
Market Dynamics: Anti-dyslipidemics - Third Generation Statins Superfluous to Market Requirements?
Commercial Perspectives: Anti-dyslipidemics - A tale of two launches
Pipeline Insight: Dyslipidemia - Shift from statins to add-ons
Antidyslipidemics - Cholesterol Absorption of Lipitors Dominance
Drugs of Tomorrow 2001: Dyslipidemia - The Advent of Third Generation and Combination Statins
Dyslipidemia - Statins Dominate Treatment Pathway - For Now
The Dyslipidemia Market: Can Growth Be Sustained as Statin Patents Expire?
Market Dynamics 2001: Anti-Dyslipidemics - Life Beyond Lipid Lowering
Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market Growth
Sector Snapshot: Statin Drug Markets
Pipeline Insight: Dyslipidemia - Pipeline Agents Unlikely To Rejuvenate The Market
|
|
|
|
